Clinical trials
Oligoprogression clinical trials
Below are recruiting oligoprogression clinical trials, each written for real people, not researchers. We’re tracking 38 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04892953RecruitingPhase 2
Durvalumab plus focused radiation for progressing stage III lung cancer
This trial studies adding focused radiation to some cancer spots in people with stage III non-small cell lung cancer (NSCLC) whose cancer did not fully stop after standard chemoradiation and durvalumab. The goal is to control a small number of growing spots (or more than a few) and improve outcomes after durvalumab.
Houston, TexasAges 18 years+ - NCT05990192RecruitingPhase 2
SBRT with or without niraparib for ovarian cancer after PARP inhibitor treatment
This trial tests a new treatment approach for people with ovarian cancer that has started to progress in a few spots (up to 3) after taking a PARP inhibitor. It combines targeted radiation (SBRT) to those spots, followed by another PARP inhibitor (niraparib), to see if this can control the cancer further.
Leeds, LeedsAges 18 years+ - NCT05102747Recruiting
Surgery-like brain radiation for up to 5 metastases
This trial compares two ways of giving focused radiation to the brain for people with a limited number of brain metastases. It aims to see which schedule works best (and is likely best for costs and quality of life).
BordeauxAges 18 years+ - NCT05301881RecruitingPhase 2
Keep the same treatment after limited metastatic growth
This study tests whether continuing your current systemic (whole-body) therapy is safe and helpful when only 1–2 metastatic spots start growing. It also checks whether adding local treatment (such as radiation or ablation) to those spots can better control the cancer.
AlkmaarAges 18 years+ - NCT05830058RecruitingPhase 2
PET-guided focused radiation for limited worsening lung, melanoma, kidney cancer
This Phase 2 study tests whether using a PET scan to guide focused radiation (SBRT) can control a small number of cancer spots that are starting to grow despite prior treatment. It may help patients avoid wider radiation by targeting only the limited progressing areas.
Duarte, CaliforniaAges 18 years+ - NCT06055881Recruiting
Using radiation to delay changing treatment for breast cancer
This trial tests whether giving radiation to a few growing spots (1-3) can let you stay on your current drug longer, instead of switching to a new one right away. It's for people with metastatic breast cancer whose disease has been stable for months but now shows limited progression.
Scottsdale, ArizonaAges 18 years+ - NCT06103669Recruiting
Local treatment for limited cancer spread
This trial tests whether using local treatments (like targeted radiation or ablation) on a few new spots of cancer can help people whose cancer is otherwise stable on their current treatment. It enrolls people with various solid tumors, such as breast, gynecologic, head & neck, sarcoma, or other types.
Sacramento, CaliforniaAges 18 years+ - NCT06260033RecruitingPhase 2
Radiation Therapy for Oligoprogressive ER+ Breast Cancer
This trial tests whether a precise radiation treatment (SBRT) can target a few growing spots of estrogen receptor-positive breast cancer that has spread to other parts of the body. It also uses a special PET scan (FES PET/CT) to see how well the cancer responds. The goal is to slow down the cancer and delay the need for stronger treatments.
Duarte, CaliforniaAges 18 years+ - NCT06523673RecruitingPhase 3
SBRT for lung cancer with limited new growth
This trial tests whether a precise type of radiation called SBRT can control lung cancer that has started to grow in only a few new spots while you are on standard treatments. It may help you delay changing to a different treatment.
Hangzhou, ZhejiangAges 18 years+ - NCT06601296RecruitingPhase 2
Radiation plus immunotherapy for metastatic kidney cancer
This trial tests whether combining radiation therapy with two types of immunotherapy (checkpoint inhibitors and an injectable drug called IMSA101) can help control metastatic kidney cancer that is only growing in a few spots. The goal is to see if this approach can shrink tumors and keep them from growing further.
Dallas, TexasAges 18 years+ - NCT06870942RecruitingPhase 2
Radiation therapy for liver cancer that progresses after first immunotherapy
This trial tests whether adding targeted radiation to liver cancer patients who have limited progression after initial immunotherapy can help control the disease. It is for people with hepatocellular carcinoma (HCC) whose cancer has started to grow in just a few spots after their first PD-1 treatment.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07193641RecruitingPhase 2
Lattice radiotherapy with standard care for slow-growing lung cancer
This trial tests whether adding a special radiotherapy technique called lattice radiotherapy to your usual cancer treatment can help control NSCLC that has started to grow in a few new spots. If you have up to 5 growing tumors and at least one measures 4.5 cm or larger, this study might be an option.
Hangzhou, ZhejiangAges 18 years+ - NCT06101277Recruiting
Local therapy for limited new cancer growth in digestive cancers
This trial tests a cancer treatment that uses local therapies (like radiation or targeted heat) to destroy a small number of growing spots. It is for people with certain gastrointestinal cancers whose main treatment is working well except for a few new spots, so they can avoid switching to a different drug right away.
Sacramento, CaliforniaAges 18 years+ - NCT06101290Recruiting
Local therapy for progressing spots in genitourinary cancers
This trial explores whether treating only the new or growing spots of cancer (called oligoprogression) with local therapies like radiation or ablation can help you stay on your current systemic treatment longer. It is for people with prostate, bladder, or kidney cancer that has started to progress in a few places.
Sacramento, CaliforniaAges 18 years+
Hear when a new Oligoprogression trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for oligoprogression?
- Yes. Clin2 currently lists 38 recruiting oligoprogression studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a oligoprogression trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a oligoprogression trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.